Announcement follows FDA's February 2025 decision to grantradiprodil Breakthrough Therapy designation Company remains on track to initiate Phase 3 pivotal trial ofradiprodil ...

of NR2b NAM for mood disorders, which is heading for late-stage testing in major depressive disorder, and in earlier development for borderline personality disorder and post-traumatic stress disorder.

There are currently no approved therapies for GRIN-related neurodevelopmental disorder. Radiprodil is an investigational, selective and potent negative allosteric modulator of the N-methyl-D-aspartate ...

Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...

Company remains on track to initiate Phase 3 pivotal trial of radiprodil in mid-2025 "We are making rapid progress in our efforts to bring a first-ever treatment for GRIN-related ...